NPAT fell 62.6% on volume weakness as cash flow doubled

The effective tax rate was essentially unchanged (28.2% vs 27.9%), so PBT and NPAT growth track within 0.1pp — this is a clean operating decline, not a tax-rate distortion.

Operating cash flow moved the opposite way, rising 111.3% to $75.6m. Capex eased 16.6% to $37.4m, producing pre-lease free cash flow of $38.2m versus a $9.1m outflow a year ago. Trade debtors fell 19.6% to $69.1m and inventories fell 8.9% to $137.7m, releasing $30.4m of operating working capital. An interim dividend of 5.39 cps was declared.

All four trading segments saw revenue contract: Delegat Limited (NZ) -13.2%, USA -18.7%, Europe -20.6%, and Australia -12.8%. Management cites "challenging consumer and inventory markets impacting case sales volumes." With fixed-cost-heavy winery economics, a 12.0% revenue contraction translated into a 17.6% EBITDA decline and a 62.5% PBT decline — implying meaningful negative operating leverage that would reverse only with volume recovery.

Cash strength is working-capital-assisted, not earnings-driven. Cash conversion of 122.6% (OCF/EBITDA) versus 47.8% prior looks transformational, but the $30.4m working-capital release explains most of the swing. Lower sales volumes shrank the receivables book and inventory carrying value; receivable days improved to 70.4 from 77.1, while inventory days actually lengthened to 140.3 from 135.6. The cash benefit is a one-time balance-sheet adjustment to a smaller revenue base.

Trailing leverage worsened despite lower absolute debt. Gross borrowings fell modestly to $353.8m and net debt to $345.6m, but net-debt-to-EBITDA on the half-year run rate weakened to 5.6x from 4.7x because EBITDA fell faster than debt. This matters because Delegat carries substantial vineyard and inventory funding, and a sustained earnings shortfall narrows headroom for further capex or dividend maintenance.

The FY24 anchor period is also flagged as carrying a discontinued operation, which distorts any H1-to-FY share comparison: HY24 NPAT of $33.4m sat against FY24 NPAT of just $7.4m, implying an H2 loss in the prior year. That makes second-half shape inferences unreliable.

What the release does support: Delegat enters H2 with materially lower inventory and receivables, lower H1 capex, and a reduced earnings base. Whether H2 volumes recover in the USA and Europe is the central unknown; the result on its own does not speak to that.

There are no flagged non-recurring items, no tax distortion, and the PBT–NPAT divergence is negligible — so the 62.6% NPAT decline is the genuine operating read. The deterioration reflects volume and margin pressure, not one-offs.

The cash result is the inverse: high reported quality, lower durability. The headline 306.0% FCF/NPAT conversion is misleading on two counts — NPAT is depressed, and the cash inflow includes a $30.4m working-capital release that cannot repeat indefinitely. Underlying recurring free cash flow, stripping the working-capital benefit, is closer to $7-8m. Capex intensity at 20.9% of revenue remains elevated for a business with declining top-line momentum, which is the more important signal for medium-term cash generation than this half's headline FCF print.

This briefing cannot assess whether the H1 volume weakness reflects a temporary destocking cycle or a structural shift in premium wine demand, because the release provides no channel-level or end-consumer data.